In addition, based on the adverse prognostic significance of TP53, NOTCH1, BIRC3, and SF3B1 mutations in CLL [25,26,27,28,29], Rossi et al. integrated mutations/disruptions into a cytogenetic model that independently predicts survival and improves prognostication of CLL patients [30]. The gene discussed is TP53; the disease is B-cell chronic lymphocytic leukemia.